glyburide has been researched along with Cardiovascular Diseases in 29 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glyburide was associated with a 52% greater risk of experiencing at least one episode of hypoglycemia compared with other secretagogues (relative risk 1." | 8.84 | A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. ( Clase, CM; Cukierman, T; Gangji, AS; Gerstein, HC; Goldsmith, CH, 2007) |
| "Glyburide was associated with a 52% greater risk of experiencing at least one episode of hypoglycemia compared with other secretagogues (relative risk 1." | 4.84 | A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. ( Clase, CM; Cukierman, T; Gangji, AS; Gerstein, HC; Goldsmith, CH, 2007) |
| "Empagliflozin (EMPA) is a sodium-glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases." | 4.02 | Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin. ( Chou, TW; Jhuo, SJ; Lai, WT; Lee, KT; Lin, YH; Liu, IH; Tasi, WC; Wu, BN, 2021) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| "Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide." | 3.74 | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007) |
| " Safety was assessed by adverse events, hypoglycemia, and body weight." | 2.78 | Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. ( Allen, E; Bryzinski, B; Cook, W; Frederich, R; Slater, J, 2013) |
| "Patients with Type 2 diabetes aged ≥ 21 years with 2-h postprandial glucose levels ≥ 11." | 2.76 | Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. ( Bellomo Damato, A; Giorgino, F; Giorgino, R; Laviola, L; Stefanelli, G, 2011) |
| "Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0." | 2.72 | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. ( Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Kravitz, BG; Lachin, JM; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| "Troglitazone therapy was associated with increases in LDL size (26." | 2.70 | Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. ( Armstrong, D; Baxi, S; Caulfield, M; Chu, NV; Deutsch, R; Henry, RR; Kim, DD; Kong, AP; Mudaliar, SR; Reaven, PD; Reitz, R, 2002) |
| "Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues." | 1.51 | Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019) |
| "Treatment with glyburide is associated with increased all-cause and cardiovascular mortality in patients with T2DM." | 1.46 | All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus. ( Esteghamati, A; Heidari, B; Larry, M; Mansournia, MA; Nakhjavani, M; Nargesi, AA; Rabizadeh, S; Raee, MR; Zarifkar, M, 2017) |
| "The objective of this study was to determine if there is a dose-response relationship between sulfonylureas and major adverse cardiovascular events (MACE)." | 1.43 | Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. ( Abdelmoneim, AS; Eurich, DT; Qiu, W; Senthilselvan, A; Simpson, SH, 2016) |
| "In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae." | 1.42 | Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015) |
| " Its use is limited by a major side effect of cardiotoxicity." | 1.39 | Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats. ( Abdel-Raheem, IT; Abouzied, MM; Taye, A, 2013) |
| "Sepsis was induced by caecal ligation and puncture (CLP) or sham surgery in Wistar rats." | 1.37 | Early potassium channel blockade improves sepsis-induced organ damage and cardiovascular dysfunction. ( Assreuy, J; Fernandes, D; Heckert, BT; Sordi, R, 2011) |
| "gliclazide treatment." | 1.35 | Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009) |
| "Because both type 2 diabetes and elevated plasma lipid levels are important independent risk factors for cardiovascular disease and coronary heart disease, the choice of an antihyperglycemic agent for patients with type 2 diabetes--in whom abnormal plasma lipid levels are often seen-should take into account effects on lipids as well as on markers of glycemic control." | 1.31 | Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. ( Dailey, GE; Fiedorek, FT; Mohideen, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Jhuo, SJ | 1 |
| Liu, IH | 1 |
| Tasi, WC | 1 |
| Chou, TW | 1 |
| Lin, YH | 1 |
| Wu, BN | 1 |
| Lee, KT | 1 |
| Lai, WT | 1 |
| Huang, HK | 1 |
| Yeh, JI | 1 |
| Abdel-Raheem, IT | 1 |
| Taye, A | 1 |
| Abouzied, MM | 1 |
| Bo, S | 1 |
| Castiglione, A | 1 |
| Ghigo, E | 1 |
| Gentile, L | 1 |
| Durazzo, M | 1 |
| Cavallo-Perin, P | 1 |
| Ciccone, G | 1 |
| Cook, W | 1 |
| Bryzinski, B | 1 |
| Slater, J | 1 |
| Frederich, R | 1 |
| Allen, E | 1 |
| Hung, YC | 1 |
| Lin, CC | 1 |
| Wang, TY | 1 |
| Chang, MP | 1 |
| Sung, FC | 1 |
| Chen, CC | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Huang, Y | 1 |
| Abdelmoneim, AS | 3 |
| Light, P | 1 |
| Qiu, W | 2 |
| Simpson, SH | 3 |
| Attia, H | 1 |
| Al-Rasheed, N | 2 |
| Faddah, L | 1 |
| Eurich, DT | 1 |
| Senthilselvan, A | 1 |
| Raee, MR | 1 |
| Nargesi, AA | 1 |
| Heidari, B | 1 |
| Mansournia, MA | 1 |
| Larry, M | 1 |
| Rabizadeh, S | 1 |
| Zarifkar, M | 1 |
| Esteghamati, A | 1 |
| Nakhjavani, M | 1 |
| Khalangot, M | 1 |
| Tronko, M | 1 |
| Kravchenko, V | 1 |
| Kovtun, V | 1 |
| Bellomo Damato, A | 1 |
| Stefanelli, G | 1 |
| Laviola, L | 1 |
| Giorgino, R | 1 |
| Giorgino, F | 1 |
| Sordi, R | 1 |
| Fernandes, D | 1 |
| Heckert, BT | 1 |
| Assreuy, J | 1 |
| Hasenbank, SE | 1 |
| Seubert, JM | 1 |
| Brocks, DR | 1 |
| Light, PE | 1 |
| Dailey, GE | 1 |
| Mohideen, P | 1 |
| Fiedorek, FT | 1 |
| Rosenthal, JH | 1 |
| Charpentier, G | 1 |
| Riveline, JP | 1 |
| Dardari, D | 1 |
| Varroud-Vial, M | 1 |
| Kahn, SE | 1 |
| Haffner, SM | 1 |
| Heise, MA | 1 |
| Herman, WH | 1 |
| Holman, RR | 1 |
| Jones, NP | 1 |
| Kravitz, BG | 1 |
| Lachin, JM | 1 |
| O'Neill, MC | 1 |
| Zinman, B | 1 |
| Viberti, G | 1 |
| Gangji, AS | 1 |
| Cukierman, T | 1 |
| Gerstein, HC | 1 |
| Goldsmith, CH | 1 |
| Clase, CM | 1 |
| Monami, M | 1 |
| Balzi, D | 1 |
| Lamanna, C | 1 |
| Barchielli, A | 1 |
| Masotti, G | 1 |
| Buiatti, E | 1 |
| Marchionni, N | 1 |
| Mannucci, E | 1 |
| Rohra, DK | 1 |
| Maheshwary, AR | 1 |
| Gauba, SS | 1 |
| Standl, E | 1 |
| Schnell, O | 1 |
| Tattersall, RB | 1 |
| Monnier, L | 1 |
| Hermann, LS | 1 |
| Ranstam, J | 1 |
| Vaaler, S | 1 |
| Melander, A | 1 |
| Chu, NV | 1 |
| Kong, AP | 1 |
| Kim, DD | 1 |
| Armstrong, D | 1 |
| Baxi, S | 1 |
| Deutsch, R | 1 |
| Caulfield, M | 1 |
| Mudaliar, SR | 1 |
| Reitz, R | 1 |
| Henry, RR | 1 |
| Reaven, PD | 1 |
| Stowers, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes[NCT02345239] | Phase 3 | 14 participants (Anticipated) | Interventional | 2015-02-28 | Not yet recruiting | ||
| Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359] | 138 participants (Anticipated) | Observational [Patient Registry] | 2019-05-06 | Recruiting | |||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus[NCT02639988] | 1,000 participants (Anticipated) | Observational | 2016-04-13 | Suspended | |||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
6 reviews available for glyburide and Cardiovascular Diseases
| Article | Year |
|---|---|
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe | 2012 |
Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
Topics: Acarbose; Adult; Aged; Aged, 80 and over; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitu | 2006 |
A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.
Topics: Cardiovascular Diseases; Diabetic Angiopathies; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents | 2007 |
[25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Topics: Aged; Aging; Blood Glucose; Cardiovascular Diseases; Chlorpropamide; Diabetes Complications; Diabete | 1984 |
Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Intolerance; Glyburide; Glycated Hemoglo | 2000 |
Oral treatment in diabetes.
Topics: Acetohexamide; Acidosis; Administration, Oral; Animals; Biguanides; Cardiovascular Diseases; Chlorpr | 1972 |
5 trials available for glyburide and Cardiovascular Diseases
| Article | Year |
|---|---|
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV | 2013 |
Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Di | 2011 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G | 2006 |
Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cholesterol; Ch | 1999 |
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Chromans; D | 2002 |
18 other studies available for glyburide and Cardiovascular Diseases
| Article | Year |
|---|---|
Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Connexin 43; Connexins; Diet, High-Fat; Dise | 2021 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2019 |
Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Rela | 2013 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Coronary Di | 2013 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular | 2015 |
The combination of zinc and glibenclamide limits cardiovascular complications in diabetic rats via multiple mechanisms.
Topics: Animals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Experimental; Glyburide | 2015 |
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Re | 2016 |
All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Coronary Angiography; Coronary Artery | 2017 |
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2009 |
Early potassium channel blockade improves sepsis-induced organ damage and cardiovascular dysfunction.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Female; Gene Expression Regulation, Enzymologic; G | 2011 |
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Topics: Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type | 2002 |
Acarbose for patients with hypertension and impaired glucose tolerance.
Topics: Acarbose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Intolerance; Glyburide; Humans | 2003 |
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 2007 |
Prevalence of cardiovascular events in diabetic patients taking sulphonylureas: need for assessment.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Pakistan | 2007 |
Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Humans; Hypogl | 2008 |
Management of type 2 diabetes: long-awaited evidence of benefits after blood sugar control.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemia; Hypoglycemic Ag | 1999 |